ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3083

Utility of Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Short Form for Understanding Interplay Between Patient-Reported Outcome Measures and Physician Driven Disease Activity Measures

Yong Gil Hwang1, Juan (June) Feng2, Heather Eng2, Jason Lyons2, Anthony Fabio2 and Larry W. Moreland1, 1Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2Epidemiology, University of Pittsburgh, School of Public Health, Pittsburgh, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, patient outcomes and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects V: Challenges in the Assessment and Management of Established RA

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:  Discordance between patient and physician assessment of rheumatoid arthritis (RA) disease activity strongly associates with pain scores. Patient-reported outcomes measurement information system (PROMIS) 29 is recommended as the preferred battery of measures to collect in musculoskeletal pain studies.  We evaluated the discordance between Routine Assessment of Patient Index 3 (RAPID3) and Clinical Disease Activity Index (CDAI) and investigated the associations between RA activity measures, discordance and patient-reported outcome measures using PROMIS29.

Methods: For RA subjects enrolled in the University of Pittsburgh Rheumatoid Arthritis Comparative Effectiveness Registry (RACER), a cross-sectional analysis was performed for all RACER patients who completed PROMIS29 short form and had RAPID3 and CDAI recorded.  Association between CDAI and RAPID3 was evaluated by the percentage of agreement, Pearson¡¯s correlation coefficient, and kappa statistics.   For subjects in remission/low disease activity by CDAI who had RAPID3 scores (0-10) consistent with near remission or low disease activity (¡Â 2) versus moderate or high disease activity (>2), predictors were determined using logistic regression.

Results: For the 363 subjects analyzed, age was 64.2 +/- 13.8 (mean +/- SD) years with disease duration of 13.9 +/- 13.1 years. CDAI was moderately correlated with RAPID3 (r=0.60, p<0.0001). PROMIS domains were correlated with RAPID3 and CDAI with various degrees (Figure). RAPID3 had strongest correlation with pain intensity (r = 0.89, p<0.001) and pain interference (r=0.84, p<0.001). Overall agreement between disease severity categories of CDAI and RAPID3 were fair (percent agreement = 40.1, kappa=0.21) (Table).  In subjects with remission to low disease activity by CDAI, pain intensity (standardized regression coefficient beta = 1.33, p<0.001) and physical function (beta = -0.21, p<0.001) among PROMIS29 domains predicted discrepancies between CDAI and RAPID (Akaike information criterion (AIC) =110.2). When pain intensity and physical function were removed from the model, pain interference (beta = 0.18, p<0.001 and impaired social roles (beta = -0.11, p=0.001) predicted discrepancies (AIC = 168.9).

Conclusion:   Discordance between CDAI and RAPID3 was frequent, especially among subjects with remission/low disease activity by CDAI. These subjects were predicted by PROMIS29 measures associated with pain intensity.  Our data suggest that PROMIS29 helps to understand the discordance between patient and physician assessment of disease activity.  

Table. Disease activity categories by Routine Assessment of Patient Index 3 (RAPID3) and Clinical Disease Activity Index (CDAI)
 

CDAI

RAPID3

Remission

Low

Moderate

High

Near remission 35 16 3 0
Low 13 27 7 0
Moderate 12 59 43 4
High 0 43 63 33

 


Disclosure: Y. G. Hwang, None; J. Feng, None; H. Eng, None; J. Lyons, None; A. Fabio, None; L. W. Moreland, None.

To cite this abstract in AMA style:

Hwang YG, Feng J, Eng H, Lyons J, Fabio A, Moreland LW. Utility of Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Short Form for Understanding Interplay Between Patient-Reported Outcome Measures and Physician Driven Disease Activity Measures [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/utility-of-patient-reported-outcomes-measurement-information-system-promis-29-short-form-for-understanding-interplay-between-patient-reported-outcome-measures-and-physician-driven-disease-activity-m/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-patient-reported-outcomes-measurement-information-system-promis-29-short-form-for-understanding-interplay-between-patient-reported-outcome-measures-and-physician-driven-disease-activity-m/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology